 |
|||
     |
|||
|
 We created lorvotuzumab mertansine (formerly IMGN901) for the treatment of cancers that express CD56. These include solid tumors, such as small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC), ovarian cancer, carcinoid and other neuroendocrine tumors. They also include multiple myeloma (MM) and certain other types of liquid cancers. Lorvotuzumab Mertansine for SCLC, MCC, Ovarian Cancer and other CD56+ Solid Tumors
We have a clinical trial underway to evaluate lorvotuzumab mertansine for these cancers. The first part of this trial tested different doses of the compound to establish its maximum tolerated dose. This phase has completed. Encouraging clinical data from this part of the study were presented at the 13th World Conference on Lung Cancer in July 2009. The findings specifically in MCC were reported separately at the AACR-NCI-EORTC conference in November 2009. Patient enrollment is now underway in the second phase of this trial, in which lorvotuzumab mertansine is administered at its maximum tolerated dose. This part focuses on SCLC, MCC, and ovarian cancer, and is being used to inform our development plan for lorvotuzumab mertansine for the treatment of CD56+ solid tumors. Lorvotuzumab Mertansine for Multiple Myeloma Our Study 003 evaluates lorvotuzumab mertansine when used as a single agent to treat MM that was previously treated with the marketed therapies. The first phase of this study was designed to establish the maximum tolerated dose of the compound. That phase has been completed and encouraging findings were reported at the ASH meeting in December 2009. Patients are now being enrolled in the expansion phase of this trial. Patient recruitment is also underway in our Study 005, which evaluates lorvotuzumab mertansine when used in combination with lenalidomide and dexamethasone. These agents were found to have synergistic activity in preclinical studies. |
||
|
|||
